cbdMD (YCBD) Income from Non-Controlling Interests (2018 - 2019)
cbdMD (YCBD) reported Income from Non-Controlling Interests of $712068.0 for Q3 2019, up 147.35% sequentially from -$1.5 million in Q2 2019.
cbdMD (YCBD) Income from Non-Controlling Interests (2018 - 2019) Analysis & Trends
cbdMD (YCBD) has 2 years of Income from Non-Controlling Interests data on file, last reported at $712068.0 in Q3 2019.
- For the quarter ending Q3 2019, Income from Non-Controlling Interests changed N/A year-over-year to $712068.0; the trailing twelve-month figure through Jun 2020 stood at $712068.0 (changed N/A YoY), and the FY2019 full-year result was -$929323.0, down 295.68% from the prior year.
- Income from Non-Controlling Interests grew to $712068.0 in Q3 2019, from -$1.5 million in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $712068.0 in Q3 2019 to a low of -$1.5 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | cbdMD | 4.82 Mn | 1.43 Mn | 3.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 712,068.00 |
| Jun 30, 2019 | -1.50 Mn |
| Mar 31, 2019 | -58,536.00 |
| Dec 31, 2018 | -79,149.00 |